Singapore markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
53.42+3.00 (+5.95%)
At close: 04:00PM EDT
53.20 -0.22 (-0.41%)
After hours: 05:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close50.42
Open52.39
Bid53.47 x 3000
Ask54.00 x 1300
Day's range52.16 - 53.55
52-week range46.93 - 58.10
Volume4,596,161
Avg. volume2,369,151
Market cap133.407B
Beta (5Y monthly)0.36
PE ratio (TTM)19.15
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.75 (3.46%)
Ex-dividend date26 May 2022
1y target estN/A
  • Financial Times

    Sanofi-GSK Covid vaccine found effective against Omicron

    Sanofi and GlaxoSmithKline have reported promising results from trials of their Covid-19 vaccine, which has proved to be particularly effective against the Omicron strain of coronavirus. The vaccine targets the original and the Beta strains of coronavirus but was also tested against the more recent Omicron variant. When used as a first dose, it demonstrated a 64.7 per cent efficacy rate against symptomatic infection overall in adults, and was 72 per cent effective against infections caused by Omicron.

  • Zacks

    Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron

    Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.

  • Financial Times

    Sanofi and GSK report ‘positive’ results from Covid booster

    Sanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicited a strong immune response against the Omicron variant. The French healthcare company said the “next-generation” booster jab delivered a “strong immune response” against variants of Covid, including Omicron, after two trials. The vaccine makers said their jab increased antibodies to tackle the BA.1 Omicron strain by 40-fold in participants who had received two messengerRNA shots, the technology used in popular vaccines from Moderna and BioNTech/Pfizer.